Briefs · Frontier Science
The First mRNA Cancer Therapy Has Passed Its Phase 3 Test
The first mRNA cancer therapy has passed its Phase 3 test — not by beating a placebo, but by beating the best drug already available.
Merck and Moderna announced on 19 August that their Phase 3 INTerpath-001 trial met its primary endpoint of recurrence-free survival and a key secondary endpoint of distant metastasis-free survival. The therapy, intismeran autogene (V940/mRNA-4157), is an individualised mRNA neoantigen treatment built from each patient’s own tumour mutations, given alongside KEYTRUDA to 1,137 patients whose stage IIB–IV melanoma had been completely resected.
It is the first positive Phase 3 readout for an individualised neoantigen therapy, and for any mRNA-based cancer therapy — and the first Phase 3 study to show a clinically meaningful improvement over KEYTRUDA alone in the adjuvant setting. Full data are still to come; overall survival is not yet mature.
Conclusion: intismeran is not a vaccine in the old sense, but rather a lesson plan — written from the tumour itself, and taught to the immune system.
Summary in our own words. The original belongs to its publisher.